drugset / Trial / NCT01139125
An Open Trial of Cysteamine Treatment in Schizophrenia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.
Timeline
- Start
- 2009-09
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cysteamine | Unknown | 2100 mg | — |